FTC: 12- to 14-year exclusivity for biotech drugs too long

06/10/2009 | Reuters

The 12- to 14-year market exclusivity sought by biotech drugmakers to protect their brand name products is too long because it will stifle innovation and chances are these companies will keep "a substantial market share" when generic counterparts gain FDA approval, according to a Federal Trade Commission report. Follow-on biologics are unlikely to be discounted more than 10% to 30% off the price of brand name medicines, according to the report.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD